Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study

BACKGROUND: Regorafenib is considered a standard of care as third-line therapy in metastatic colorectal cancers (mCRCs). MATERIALS AND METHODS: The study was based on a computerized clinical data form sent to oncologists across the country for entry of anonymized patient data. The data entry form wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramaswamy, Anant, Ostwal, Vikas, Pande, Nikhil, Sharma, Atul, Patil, Shekar, Thippeswamy, Ravi, Ghadyalpatil, Nikhil, Roy, Rakesh, Peshwe, Harish, Poladia, Bhavesh, Rajamanickam, Deepan, Rangarajan, Bharat, Neelesh Reddy, P. R., Pandita, Vimal, Mukherjee, Ashis, Thoke, Aniket, Sarkar, Abhijit, Satish, C. T., Shashidara, H., Banavali, S. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
ORIGINAL ARTICLE: GI Cancers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348777/
https://www.ncbi.nlm.nih.gov/pubmed/30766846
http://dx.doi.org/10.4103/sajc.sajc_173_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348777/
https://www.ncbi.nlm.nih.gov/pubmed/30766846
http://dx.doi.org/10.4103/sajc.sajc_173_18

Ejemplares similares